Education and Training
A Study of Vismodegib With Surgery in Participants With Previously Untreated Basal Cell Carcinoma
This randomized, double-blind, placebo-controlled study will assess the efficacy and safety of vismodegib with surgery in participants with basal cell carcinoma.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: vismodegib
- drug: Placebo
Eligibility
Inclusion Criteria:
- Diagnosis of non-infected, not recurrent, previously untreated basal cell carcinoma
- Free of any significant physical abnormalities (e.g., tattoos) at the target basal
cell carcinoma site
- Willing and able to participate in the study as an outpatient and agreement to make
frequent visits to the clinic during the treatment and follow-up periods and to comply
with study requirements
Exclusion Criteria:
- Prior treatment with vismodegib
- Known hypersensitivity to any of the study drug excipients
- Any metastatic basal cell carcinoma
- Any locally advanced basal cell carcinoma considered to be inoperable or to have a
medical contraindication to surgery
- Evidence of clinically significant and unstable diseases or conditions (e.g.,
cardiovascular, immunosuppressive, hematologic)
- Any dermatological disease at the target basal cell carcinoma site that may cause
difficulty with examination
- Recent, current, or planned participation in another experimental drug study
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061
Not Recruiting